CF PHARMTECH (02652) saw its shares rise more than 21% during the morning session. At the time of writing, the stock was up 14.54%, trading at HK$28.2, with a turnover of HK$81.96 million. The surge follows recent news that the company's self-developed inhaled powder ICF001, a改良型新药 (chemical drug category 2.1改良型新药) for treating pulmonary arterial hypertension (PAH) and interstitial lung disease-associated pulmonary arterial hypertension (PH-ILD), has had its Investigational New Drug (IND) application formally accepted by China's National Medical Products Administration (NMPA). This marks the company's second吸入制剂改良型创新药 to receive acceptance, following ICF004, signaling that its innovative pipeline in advanced respiratory formulations is accelerating into a harvest period. Starting March 9, CF PHARMTECH was officially included in the Hong Kong Stock Connect list of eligible securities. The board anticipates that this inclusion will help broaden the company's shareholder base and enhance the trading liquidity of its H-shares. A recent research report from Huaxin Securities noted that the company continues to focus on innovation, with its new PAH treatment drug expected to file an IND application within the year. Considering the sequential clinical application submissions of the company's globally patented innovative drugs, Huaxin Securities has assigned a "Buy" investment rating.